Comparative Pharmacology
Head-to-head clinical analysis: HAILEY FE 1 5 30 versus HAILEY FE 1 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HAILEY FE 1 5 30 versus HAILEY FE 1 20.
HAILEY FE 1.5/30 vs HAILEY FE 1/20
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Combination estrogen-progestin contraceptive that suppresses gonadotropin release (FSH and LH) from the pituitary, inhibiting ovulation. Additionally, increases viscosity of cervical mucus and alters endometrial receptivity.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin (FSH and LH) release via negative feedback on the hypothalamic-pituitary-ovarian axis, inhibiting ovulation. Also alters cervical mucus and endometrial lining to impair sperm penetration and implantation.
Prevention of pregnancyAcne vulgaris (off-label for females ≥15 years)Irregular menstruation (off-label)
FDA-approved for prevention of pregnancy.
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo tablets.
One tablet orally once daily for 21 consecutive days followed by 7 days of placebo tablets.
None Documented
None Documented
Ethinyl estradiol: terminal half-life ~17-24 hours; norethindrone: terminal half-life ~5-14 hours (mean 11 hours). The clinical significance is that steady-state is reached within 5-7 days.
Ethinyl estradiol: approximately 17 ± 5 hours (terminal); Norethindrone: approximately 8 ± 2 hours (terminal). Clinical context: Steady-state reached within 7-10 days; once-daily dosing maintains effective concentrations for contraceptive efficacy.
Ethinyl estradiol: primarily metabolized by CYP3A4 via hydroxylation; undergoes first-pass metabolism in the liver and gut wall. Norethindrone: primarily metabolized via reduction followed by glucuronide conjugation; some involvement of CYP3A4.
Ethinyl estradiol is primarily metabolized via CYP3A4 hydroxylation and conjugation (glucuronidation/sulfation). Norethindrone is metabolized by reduction, hydroxylation, and conjugation, primarily via CYP3A4.
Ethinyl estradiol is primarily excreted renally (40-45%) and via bile/feces (45-55%). Norethindrone is excreted 50-60% renally and 30-40% fecally.
Renal (approximately 50-60% as metabolites, including glucuronide conjugates of ethinyl estradiol and norethindrone, and about 20% as unchanged norethindrone); Fecal (approximately 30-40% as metabolites); Biliary (minor, with enterohepatic circulation of ethinyl estradiol conjugates).
Ethinyl estradiol: ~97-98% bound to albumin; norethindrone: ~95% bound to albumin and sex hormone-binding globulin (SHBG).
Ethinyl estradiol: approximately 97-98% bound to albumin (primarily) and sex hormone-binding globulin (SHBG); Norethindrone: approximately 93-95% bound to albumin and SHBG.
Ethinyl estradiol: ~2-4 L/kg; norethindrone: ~2-4 L/kg. Reflects extensive tissue distribution.
Ethinyl estradiol: approximately 2-4 L/kg; Norethindrone: approximately 4-6 L/kg. Clinical meaning: Extensive tissue distribution, with accumulation in adipose tissue and reproductive organs.
Ethinyl estradiol: 40-50% due to first-pass metabolism; norethindrone: 50-70% due to first-pass metabolism.
Oral: Ethinyl estradiol ~40-45% (first-pass metabolism); Norethindrone ~60-65% (first-pass metabolism).
No dosage adjustment required for renal impairment. Use with caution in severe renal impairment due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to risk of hyperkalemia.
Contraindicated in acute hepatitis, severe cirrhosis (Child-Pugh C), or liver tumors. For mild hepatic impairment (Child-Pugh A), no adjustment; use with caution.
Contraindicated in patients with active liver disease or Child-Pugh class B or C cirrhosis. For Child-Pugh class A, use with caution and monitor liver function.
Not indicated for premenarchal girls. For postmenarchal adolescents, same dosing as adults.
Not indicated for use before menarche. For post-menarchal adolescents, same dosing as adults: one tablet orally once daily for 21 days, then 7 days of placebo.
Not indicated for postmenopausal women due to higher risk of thromboembolic events and lack of efficacy for contraception in this population.
Not indicated for use in postmenopausal women. No specific geriatric dosing adjustments; consider increased risk of thromboembolic events and cardiovascular disease.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially in women over 35) and with heavy smoking (≥15 cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events (e.g., stroke, myocardial infarction, thromboembolism) from combination oral contraceptives. Risk increases with age (>35 years) and heavy smoking (≥15 cigarettes/day). Women who are >35 years old and smoke should not use this product.
["Risk of thromboembolic disorders and thrombotic events (e.g., MI, stroke, DVT, PE)","Increased risk of cervical cancer and breast cancer (controversial)","Hepatic neoplasia (benign and malignant)","Gallbladder disease","Hypertension","Impaired liver function","Carbohydrate and lipid effects","Headache/migraine","Bleeding irregularities","Ocular lesions (e.g., retinal thrombosis)","Depression","Contact lens intolerance","Fluid retention"]
["Increased risk of thrombotic disorders including venous thromboembolism, stroke, and myocardial infarction.","Discontinue if sudden partial or complete loss of vision or onset of proptosis, diplopia, migraine.","Elevated blood pressure; use caution in hypertension.","Gallbladder disease; increased risk of gallstones.","Carbohydrate and lipid metabolism effects; use caution in diabetes and hyperlipidemia.","Hepatic neoplasia; discontinue if jaundice or liver dysfunction.","Chloasma; avoid sun or UV exposure.","Bleeding irregularities; may cause breakthrough bleeding and spotting.","Possible decreased efficacy with concomitant enzyme-inducing drugs."]
["Current or history of thrombophlebitis or thromboembolic disorders","Cerebrovascular or coronary artery disease","Known or suspected breast cancer or personal history of breast cancer","Carcinoma of the endometrium or other estrogen-dependent neoplasia","Undiagnosed abnormal genital bleeding","Cholestatic jaundice of pregnancy or jaundice with prior OCP use","Hepatic adenomas or carcinomas","Known or suspected pregnancy","Hypersensitivity to any component","Major surgery with prolonged immobilization","Smoking in women over 35 years old","Current or history of migraine with focal aura if >35 years old","Current or history of hypertension with vascular disease"]
["Thrombophlebitis or thromboembolic disorders (current or history).","Cerebrovascular or coronary artery disease (current or history).","Known or suspected breast carcinoma or estrogen-dependent neoplasia.","Undiagnosed abnormal genital bleeding.","Pregnancy (known or suspected).","Benign or malignant liver tumor (active or history).","Active liver disease with abnormal liver function.","Hypersensitivity to any component.","Age >35 years with cigarette smoking."]
Data Pending Review
Data Pending Review
No significant food interactions. Grapefruit juice may increase ethinyl estradiol levels but effect is not clinically significant; no restriction. Iron absorption may be enhanced by vitamin C (e.g., citrus); avoid taking with dairy or antacids that reduce iron absorption, separate by at least 2 hours if needed.
No specific food interactions. Grapefruit juice may increase estrogen levels; avoid excessive consumption. St. John's Wort may reduce efficacy. Consistent intake with or without food is recommended to maintain steady-state levels.
Category X: Contraindicated in pregnancy. First trimester: Increased risk of neural tube defects, cardiovascular anomalies, and limb reduction defects. Second/third trimesters: Associated with fetal adrenal suppression, hepatic dysfunction, and masculinization of female fetuses. Discontinue immediately if pregnancy occurs.
First trimester: No increased risk of major birth defects in large epidemiological studies. Second and third trimesters: Use is not recommended due to potential adverse effects on fetal development, including possible estrogenic effects and association with congenital anomalies in animal studies. Fetal risk cannot be ruled out.
Excreted in breast milk in low amounts (estrogen M/P ratio ~0.2; progestin M/P ~0.3). Theoretical risk of reduced milk production and infant jaundice. Use only if benefits outweigh risks; consider alternative contraception.
Excreted in breast milk in small amounts. Estrogen and progestin levels may affect milk composition and reduce milk production. M/P ratio not reported; use caution, especially in the immediate postpartum period. Avoid use in breastfeeding women if possible.
Contraindicated in pregnancy. No indication for use; pharmacokinetic changes (increased clearance, protein binding changes) are irrelevant as use is prohibited.
No dose adjustment established; use is contraindicated during pregnancy. If inadvertent exposure occurs, discontinue immediately. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) do not warrant dose adjustment because the drug is contraindicated.
Category C
Category C
HAILEY FE 1.5/30 is a combination oral contraceptive containing ethinyl estradiol 30 µg and norethindrone 1.5 mg, with iron supplementation (ferrous fumarate 75 mg). The iron component is not part of the contraceptive effect but helps maintain iron stores during menstruation. It is typically taken for 21 active pills followed by 7 placebo pills (containing iron). Administer consistently at the same time daily to maintain hormone levels and minimize breakthrough bleeding. Monitor for elevated blood pressure, thromboembolic events, and hepatic adenoma. Smoking increases cardiovascular risk; avoid in women over 35 who smoke. Efficacy may be reduced with hepatic enzyme-inducing drugs (e.g., rifampin, certain anticonvulsants).
Contains ethinyl estradiol 20 mcg and norethindrone 1 mg. Consider lower estrogen dose for patients with estrogen-sensitive migraines or history of thromboembolism. Monitor for breakthrough bleeding, especially in first 3 cycles. CYP3A4 inducers like rifampin may reduce efficacy. Check pregnancy test before initiating if delayed menses. Use with caution in patients with hypertriglyceridemia.
Take one tablet daily at the same time each day, even if you do not have sex.The first 21 pills are active hormones; the last 7 pills (green) contain iron and are placebos.If you miss a pill, follow the package instructions: take the missed pill as soon as remembered, and use backup contraception if you miss more than one.Common side effects include nausea, breast tenderness, and breakthrough bleeding, especially in the first few months.Smoking while on this pill increases risk of serious cardiovascular events; do not smoke.Contact your healthcare provider if you experience leg pain, chest pain, sudden severe headache, or visual changes.HAILEY FE does not protect against HIV or other sexually transmitted infections; use condoms for protection.Inform your doctor of all medications you take, including over-the-counter drugs and supplements.If you have severe vomiting or diarrhea, use additional contraception.Store at room temperature away from moisture and heat.
Take one tablet daily at the same time, in the order listed on the pack.If you miss a dose, take it as soon as remembered; if more than 24 hours late, use backup contraception.Common side effects: nausea, breast tenderness, spotting, and headache.Report signs of blood clots: sudden leg pain, chest pain, or shortness of breath.Smoking increases risk of serious cardiovascular side effects, especially if over 35 years old.Antibiotics (except rifampin) do not reduce effectiveness; inform your provider about all medications.